The Rock-It Company Appoints David Byrnes as Chief Financial Officer
18.12.2025 16:00:00 EET | Business Wire | Press release
The Rock-It Company, the global leader in specialty logistics across live events and luxury goods, announced today the appointment of David Byrnes as Chief Financial Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218600008/en/
David Byrnes, Chief Financial Officer, The Rock-It Company
With decades of experience steering groundbreaking multimedia and live experience projects globally, David joins The Rock-It Company from Sphere Entertainment, where he most recently served as Executive Vice President and Chief Financial Officer. His career includes multiple senior leadership roles, including CFO of Madison Square Garden Entertainment Corp., Executive Vice President of Corporate Finance at Paramount, and a variety of senior leadership positions at CBS Corporation. He also spent five years at ADP, including serving as a divisional CFO, and began his career with 11 years at KPMG. David is a graduate of Pace University and earned his MBA from Columbia Business School.
“I’m thrilled to welcome David to the team. As I got to know David, I was incredibly impressed by his leadership, deep financial acumen, and strategic thinking. More importantly, I was impressed by David as a person, and I am confident that he will be a strong cultural fit at Rock-It,” said Daniel Rosenthal, President & CEO of The Rock-It Company.
“The Rock-It Company is at an incredible moment of growth, and I’m excited to step into the CFO role to help support the continued momentum the company is seeing worldwide,” said Byrnes. “I have been inspired by Dan’s vision and am impressed by the team he has assembled to drive end-market expansion across all sectors. I look forward to partnering with the team to help bring The Rock-It Company into its next chapter of success and development.”
Rob Hull, current Interim CFO, will continue with The Rock-It Company as Vice Chairman. “I am extremely grateful to Rob for his steadfast leadership and esprit de corps. In just four months, he has spearheaded material improvements to our financial team, process, and technology. This foundation will be an important asset to David,” said Daniel Rosenthal.
About The Rock-It Company
The Rock-It Company (formerly Global Critical Logistics) is the global leader in mission-critical specialty logistics, trusted to move irreplaceable assets and power extraordinary moments across Live Events and Luxury Goods. Built on a 47-year legacy, Rock-It delivers multimodal freight forwarding, event logistics planning, specialized packing and storage, customs and ATA carnet services, insurance, on-site support, and more.
Rock-It manages the logistics behind concert touring, major sporting events, broadcast productions, film and media, corporate events, experiential activations, rapid response and infrastructure, and the transport and protection of fine art, rare automobiles, and other priceless collections. With access across 160+ countries and with more than 10,000 missions each year, Rock-It serves a diverse list of partners including the FIFA World Cup 2026, the Pebble Beach Concours D’Elegance, RM Sotheby’s, leading hypercar OEMs, multiple Olympic committees, leagues and federations, and other leading brands across the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218600008/en/
Contacts
Media Contact
Angus Brown
angus.brown@rockitcompany.com
+1 (212) 507-9689
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom